Sciences (NASDAQ: GILD) is quite a famous pharmaceutical company these days.
It’s antiviral redeliver is the hot drug of the moment due to its apparent
success in clinical trials with patients who have COVID-19, the disease caused
by the SARS-CoV-2 coronavirus.
hot drug leads to a lot of interest in a stock, which is the key reason why
Gilead’s shares have generally been on the rise since the world became
reacquainted or initially acquainted with redelivering (formerly a treatment
for Ebola). But I think that as an investment, the company has another very
attractive factor that isn’t getting quite so much attention — or any at all.
is seeing strong early results for antiviral medicine remdesivir. That sent
Gilead stock soaring 12% early Friday. For the coronavirus stock market rally,
the Gilead remdesivir news raises hope that an effective treatment will make it
easier to open up the economy.
Prime Minister Shinzo Abe revealed on Monday the country’s plan to develop the
COVID-19 vaccine outlines clinical trials on humans could begin in July.
pharmaceutical companies have already begun tests of experimental vaccines to
find a permanent treatment for the novel coronavirus, including Moderna and
Pfizer, both based in the United States.
the Asian country is preparing to lift the state of emergency, its Health
Ministry approved Gilead Sciences’ drug remdesivir for use against the disease.
the other side of the world, The Trump administration has mishandled efforts to
deliver the antiviral drug remdesivir to parts of the country that need the
possible COVID-19 treatment the most, according to a report from Axios.
unnamed sources familiar with the talks, a “complete breakdown” in
communication and coordination within the administration has led to a failure
to deliver the drug to high-priority hospitals. The report also notes no one
has assumed responsibility for the alleged delays.
drug manufactured by Gilead Sciences has shown promising results in clinical
trials as a treatment for the coronavirus and was donated by the company to the
federal government after receiving special authorization from the Food and Drug
only drug given emergency authorization by the Food and Drug Administration to
treat patients with the coronavirus has arrived in Illinois, and more than 90%
of it will go to patients being treated at hospitals in Cook County.
All information on this website is of a general nature. The information is not adapted to conditions that are specific to your person or entity. The information provided can not be considered as personal, professional or legal advice or investment advice to the user.
Signal Factory is not represented as a registered investment consultant or brokerage dealer nor offers to buy or sell any of the financial instruments mentioned in the service offered.
While Signal Factory believes that the content provided is accurate, there are no explicit or implied warranties of accuracy. The information provided is believed to be reliable; Signal Factory does not guarantee the accuracy or completeness of the information provided. Third parties refer to Signal Factory to provide technology and information if a third party fails, and then there is a risk that the information may be delayed or not delivered at all.
All information and comments contained on this website, including but not limited to, opinions, analyzes, news, prices, research, and general, do not constitute investment advice or an invitation to buy or sell any type of instrument. Signal Factory assumes no responsibility for any loss or damage that may result, directly or indirectly, from the use or dependence on such information.
All information contained on this web site is a personal opinion or belief of the author. None of these data is a recommendation or financial advice in any sense, also within the meaning of any commercial act or law. Writers, publishers and affiliates of Signal Factory are not responsible for your trading in any way.
The information and opinions contained in the site are provided for information only and for educational reasons, should never be considered as direct or indirect advice to open a trading account and / or invest money in Forex trading with any Forex company . Signal Factory assumes no responsibility for any decisions taken by the user to create a merchant account with any of the brokers listed on this website. Anyone who decides to set up a merchant account or use the services, free of charge or paid, to any of the Forex companies mentioned on this website, bears full responsibility for their actions.
Any institution that offers a service and is listed on this website, including forex brokers, financial companies and other institutions, is present only for informational purposes. All ratings, ratings, banners, reviews, or other information found for any of the above-mentioned institutions are provided in a strictly objective manner and according to the best possible reflection of the materials on the official website of the company.
Forex trading is potentially high risk and may not be suitable for all investors. The high level of leverage can work both for and against merchants. Before each Forex investment, you should carefully consider your goals, past experience and risk level. The opinions and data contained on this site should not be considered as suggestions or advice for the sale or purchase of currency or other instruments. Past results do not show or guarantee future results.
Neither Signal Factory nor its affiliates ensure the accuracy of the content provided on this Site. You explicitly agree that viewing, visiting or using this website is at your own risk.